TY - JOUR
T1 - The evolving cystic fibrosis microbiome
T2 - A comparative cohort study spanning 16 years
AU - Acosta, Nicole
AU - Whelan, Fiona J.
AU - Somayaji, Ranjani
AU - Poonja, Ali
AU - Surette, Michael G.
AU - Rabin, Harvey R.
AU - Parkins, Michael D.
N1 - Publisher Copyright:
© 2017 by the American Thoracic Society.
PY - 2017/8
Y1 - 2017/8
N2 - Rationale: The cystic fibrosis (CF) airways are infected with a diverse polymicrobial community. Objectives: Understanding how changes in the CF microbiome have occurred over time, similar to the observed changes in the prevalence of cultured pathogens, is key in understanding the microbiome's role in disease. Methods: Drawing from a prospectively collected and maintained sputum biobank, we identified 45 patients with sputum samples collected between the ages of 18 and 21 years in three successive cohorts of adults transitioning to our CF clinic: A (1997-2000), B (2004-2007), and C (2010-2013). Patient demographics, clinical status, and medications were collected from detailed chart review. Microbial communities were assessed by Ilumina MiSeq sequencing of the variable 3 (V3) region of the 16S rDNA. Results: The three cohorts were similar with respect to baseline demographics. Therewas a trend toward improved health and use of disease-modifying therapies in each successive cohort. Shannon diversity increased in the most recent cohort, suggesting an increase in the diversity of organisms between cohorts. Furthermore, the proportion of samples with Pseudomonas-dominated communities decreased over time, whereas Streptococcus increased. Although b-diversity was associated with transitioncohort, thegreatest predictorofdiversityremained lung function. Furthermore, coremicrobiome constituentswerepreserved across cohorts. Conclusions: Modest changes in the composition and structure of the microbiome of three successive cohorts of young adults with CF were observed, occurring in parallel with successive improvements in clinical status. Importantly, however, the core microbiome constituents were preserved across cohorts.
AB - Rationale: The cystic fibrosis (CF) airways are infected with a diverse polymicrobial community. Objectives: Understanding how changes in the CF microbiome have occurred over time, similar to the observed changes in the prevalence of cultured pathogens, is key in understanding the microbiome's role in disease. Methods: Drawing from a prospectively collected and maintained sputum biobank, we identified 45 patients with sputum samples collected between the ages of 18 and 21 years in three successive cohorts of adults transitioning to our CF clinic: A (1997-2000), B (2004-2007), and C (2010-2013). Patient demographics, clinical status, and medications were collected from detailed chart review. Microbial communities were assessed by Ilumina MiSeq sequencing of the variable 3 (V3) region of the 16S rDNA. Results: The three cohorts were similar with respect to baseline demographics. Therewas a trend toward improved health and use of disease-modifying therapies in each successive cohort. Shannon diversity increased in the most recent cohort, suggesting an increase in the diversity of organisms between cohorts. Furthermore, the proportion of samples with Pseudomonas-dominated communities decreased over time, whereas Streptococcus increased. Although b-diversity was associated with transitioncohort, thegreatest predictorofdiversityremained lung function. Furthermore, coremicrobiome constituentswerepreserved across cohorts. Conclusions: Modest changes in the composition and structure of the microbiome of three successive cohorts of young adults with CF were observed, occurring in parallel with successive improvements in clinical status. Importantly, however, the core microbiome constituents were preserved across cohorts.
KW - Biomarker
KW - Emerging pathogens
KW - Lung microbiota
KW - Pseudomonas aeruginosa
KW - Streptococcus
UR - http://www.scopus.com/inward/record.url?scp=85026771754&partnerID=8YFLogxK
U2 - 10.1513/AnnalsATS.201609-668OC
DO - 10.1513/AnnalsATS.201609-668OC
M3 - Article
C2 - 28541746
AN - SCOPUS:85026771754
SN - 2325-6621
VL - 14
SP - 1288
EP - 1297
JO - Annals of the American Thoracic Society
JF - Annals of the American Thoracic Society
IS - 8
ER -